These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 11772315)

  • 1. Botulinum toxin type B: a new injectable treatment for cervical dystonia.
    Brashear A
    Expert Opin Investig Drugs; 2001 Dec; 10(12):2191-9. PubMed ID: 11772315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The botulinum toxins in the treatment of cervical dystonia.
    Brashear A
    Semin Neurol; 2001; 21(1):85-90. PubMed ID: 11346029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Botulinum toxin type B in the management of dystonia non-responsive to botulinum toxin type A].
    Cardoso F
    Arq Neuropsiquiatr; 2003 Sep; 61(3A):607-10. PubMed ID: 14513166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials.
    Lew MF; Brashear A; Factor S
    Neurology; 2000; 55(12 Suppl 5):S29-35. PubMed ID: 11188982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on the botulinum neurotoxins.
    Carruthers A; Carruthers J
    Skin Therapy Lett; 2001 Dec; 6(13):1-2. PubMed ID: 11813096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Botulinum toxin for the treatment of cervical dystonia.
    Tintner R; Jankovic J
    Expert Opin Pharmacother; 2001 Dec; 2(12):1985-94. PubMed ID: 11825330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for treatment of axillary hyperhidrosis.
    Baumann L; Slezinger A; Halem M; Vujevich J; Martin LK; Black L; Bryde J
    Int J Dermatol; 2005 May; 44(5):418-24. PubMed ID: 15869543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. British Neurotoxin Network recommendations for managing cervical dystonia in patients with a poor response to botulinum toxin.
    Marion MH; Humberstone M; Grunewald R; Wimalaratna S
    Pract Neurol; 2016 Aug; 16(4):288-95. PubMed ID: 26976927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of botulinum toxin injections for spasmodic torticollis of tardive dystonia.
    Kaufman DM
    J Neuropsychiatry Clin Neurosci; 1994; 6(1):50-3. PubMed ID: 8148637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BotB (botulinum toxin type B): evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study).
    Truong DD; Cullis PA; O'Brien CF; Koller M; Villegas TP; Wallace JD
    Mov Disord; 1997 Sep; 12(5):772-5. PubMed ID: 9380065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia.
    Chapman MA; Barron R; Tanis DC; Gill CE; Charles PD
    Clin Ther; 2007 Jul; 29(7):1325-37. PubMed ID: 17825685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Botulinum toxin B: a review of its therapeutic potential in the management of cervical dystonia.
    Figgitt DP; Noble S
    Drugs; 2002; 62(4):705-22. PubMed ID: 11893235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum toxin-B and the management of hyperhidrosis.
    Baumann LS; Halem ML
    Clin Dermatol; 2004; 22(1):60-5. PubMed ID: 15158547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of a new bulk toxin of botulinum toxin in cervical dystonia: a blinded evaluation.
    Racette BA; McGee-Minnich L; Perlmutter JS
    Clin Neuropharmacol; 1999; 22(6):337-9. PubMed ID: 10626093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety and tolerability of botulinum toxins for the treatment of cervical dystonia.
    Brashear A
    Expert Opin Drug Saf; 2005 Mar; 4(2):241-9. PubMed ID: 15794717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of botulinum toxin type-B in the treatment of patients who have become unresponsive to botulinum toxin type-A -- initial experiences.
    Barnes MP; Best D; Kidd L; Roberts B; Stark S; Weeks P; Whitaker J
    Eur J Neurol; 2005 Dec; 12(12):947-55. PubMed ID: 16324088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human T-cell responses to botulinum neurotoxin. Responses in vitro of lymphocytes from patients with cervical dystonia and/or other movement disorders treated with BoNT/A or BoNT/B.
    Oshima M; Deitiker PR; Jankovic J; Duane DD; Aoki KR; Atassi MZ
    J Neuroimmunol; 2011 Dec; 240-241():121-8. PubMed ID: 22079193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence-based medicine in botulinum toxin therapy for cervical dystonia.
    Ceballos-Baumann AO
    J Neurol; 2001 Apr; 248 Suppl 1():14-20. PubMed ID: 11357233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.
    Brashear A; Lew MF; Dykstra DD; Comella CL; Factor SA; Rodnitzky RL; Trosch R; Singer C; Brin MF; Murray JJ; Wallace JD; Willmer-Hulme A; Koller M
    Neurology; 1999 Oct; 53(7):1439-46. PubMed ID: 10534248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Botulinum toxin type B (MyoBloc) in the management of hyperkinetic facial lines.
    Ramirez AL; Reeck J; Maas CS
    Otolaryngol Head Neck Surg; 2002 May; 126(5):459-67. PubMed ID: 12075218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.